Long Noncoding RNA Serve as a Potential Predictive Biomarker for Breast Cancer: A Meta-Analysis

Table 1

Intervening characteristics of the included trials.

First author, year	Ethnicity	Pathologic type (E/C)	Sample size (E/C)	Specimen	lncRNA	State	Cutoff value	TP	FP	FN	TN	QUADAS-2
Dong, 2018	Asian	BC/ANCTs	36/36	Tissue	SNHG14	Up	Unclear	25	7	11	29	5
Du, 2018	Asian	TNBC/health	100/50	Plasma	ANRIL	Up	9.113	87	2	13	48	6
					SOX2OT	Up	9.113	72	7	28	43
					ANRASSF1	Up	9.113	57	13	43	37
Ghafouri, 2019	Caucasian	IDC/ANCTs	54/54	Tissue	FAS-AS	Down	Unclear	29	30	25	14	6
					TUG1	Down	Unclear	16	5	38	49
					OIP5-AS1	Down	Unclear	48	37	6	17
					NEAT1	Down	Unclear	41	34	13	20
					HULC	Down	Unclear	9	1	45	53
Huang, 2018	Asian	TNBC/health	30/30	Serum	MALAT1	Up	0.62	19	10	11	20	7
			128/77		MALAT1	Up	2.1345	121	15	7	62
Khorshidi, 2018	Caucasian	IDC/ANCTs	54/54	Tissue	DSCAM-AS1	Up	Unclear	30	13	24	41	6
Li, 2018	Asian	TNBC/health	48/47	Serum	LINC00310	Up	1.402	37	6	11	41	4
Li, 2016	Asian	IDC/ANCTs	90/90	Tissue	GAS6-AS1	Down	5.21	43	17	47	73	6
Liu, 2017	Asian	TNBC/health	60/40	Plasma	ANRIL	Up	Unclear	45	6	15	34	5
					HIF1A-AS2	Up	Unclear	42	6	18	34
					UCA1	Up	Unclear	48	8	12	32
Miao, 2016	Asian	BC/BBD	78/40	Serum	MALAT1	Up	Unclear	55	4	23	36	4
Zidan, 2018	Caucasian	TNBC/health	80/80	Serum	MALAT1	Up	2.6	67	15	13	65	5
Nie, 2107	Asian	BC/ANCTs	110/110	Tissue	Z38	Up	2.86	86	33	24	77	5
Farzaneh, 2108	Caucasian	BC/ANCTs	15/15	Tissue	ARA	Up	Unclear	15	0	0	15	4
Ravanbakhsh, 2019	Caucasian	IDC/ANCTs	52/52	Tissue	USMycN	Up	17.5	44	19	8	23	5
Taherian, 2019	Caucasian	BC/ANCTs	80/80	Tissue	SNHG1	Up	Unclear	53	34	27	46	7
					SNHG5	Up	Unclear	43	21	37	59
Wang, 2018	Asian	TNBC/health	68/64	Plasma	AWPPH	Up	Unclear					5
Wu, 2018	Asian	BC/health	102/50	Plasma	MALAT1	Up	Unclear	55	7	47	43	6
Xu, 2015	Asian	BC/health	68/68	Serum	RP11-445H22.4	Up	0.3	63	18	5	50	7
Yang, 2019	Asian	TNBC/health	26/38	Plasma	POU3F3	Up	Unclear					5
Zhang, 2018	Asian	BC/non-BC	30/30	Plasma	ROR	Up	1.205	24	13	6	17	7
Zhang, 2016	Asian	BC/health	30/30	Plasma	H19	Up	Unclear	17	4	13	26	5
Zhang, 2016	Asian	BC/health	70/86	Plasma	HOTAIR	Up	Unclear	51	6	19	80	4
Zhang, 2015	Asian	BC/health	100/104	Serum	HOTAIR	Up	0.3	80	33	20	71	6
Zhang, 2017	Asian	BC/health	66/40	Serum	MALAT1	Up	Unclear	48	15	18	25	4
Zhang, 2016	Asian	BC/health	88/100	Plasma	HOTAIR	Up	Unclear	61	7	17	93	6
Zhao, 2018	Asian	BC/health	36/32	Serum	XIST	Down	13.1	28	11	8	21	4
Zhao, 2017	Asian	BC/health	96/90	Plasma	ROR	Up	1.384	77	24	19	66	7
Cui, 2018	Asian	BC/health	90/94	Serum	LSINCT5	Up	1.433	36	0	54	94	7
Li, 2018	Asian	BC/health	76/80	Plasma	CRNDE	Up	Unclear	61	32	15	48	4
Li, 2018	Asian	BC/ANCTs	64/64	Tissue	MALAT1	Up	Unclear	50	22	14	42	4
Lin, 2018	Asian	BC/health	50/25	Plasma exosome	H19	Up	1.64	35	7	15	18	5
				Plasma	H19	Up	1.555	35	10	15	15
Lin, 2018	Asian	BC/health	50/25	Plasma exosome	MALAT1	Up	0.743	42	12	8	13	5
Liu, 2016	Asian	BC/BBD	86/60	Serum	H19	Up	Unclear	60	10	26	50	4
					HOTAIR	Up	Unclear	69	14	17	46
					MALAT1	Up	Unclear	69	18	17	42
Yang, 2018	Asian	BC/BBD	60/60	Plasma	MALAT1	Up	Unclear	58	4	2	56	4
Ye, 2017	Asian	BC/health	124/48	Plasma	HIT	Down	Unclear	103	16	21	32	4
Zhang, 2016	Asian	BC/health	30/42	Urine	H19	Up	Unclear	22	14	8	28	4

Note: E/C: experimental group/control group; TP: true positive; FP: false positive; FN: false negative; TN: true negative; QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies 2; BC: breast cancer; IDC: invasive ductal carcinoma; TNBC: triple-negative breast cancer; ANCTs: adjacent nontumor tissues; BBD: benign breast disease; MGF: mammary gland fibroma.